(DCTH) Delcath Systems - Ratings and Ratios

Delcath Systems, Inc. (NASDAQ:DCTH), a leader in interventional oncology, specializes in innovative treatments for primary and metastatic liver cancers. The companys flagship product, HEPZATO KIT, represents a significant advancement in targeted chemotherapy delivery. This system combines melphalan with a hepatic delivery mechanism designed to maximize therapeutic impact while minimizing systemic exposure, thereby reducing adverse side effects. HEPZATO is currently under evaluation in the FOCUS clinical trial, which is investigating its efficacy in treating metastatic hepatic dominant Uveal Melanoma, with a primary focus on objective response rate. Beyond its investigational use, Delcath also markets the CHEMOSAT Hepatic Delivery System in Europe, enabling medical centers to administer melphalan for a range of liver cancers under approved indications. Established in 1988, Delcath is headquartered in New York, New York, and maintains a strong presence in both the U.S. and European markets. Web URL: https://www.delcath.com.

From a stock performance perspective, Delcath Systems, Inc. (NASDAQ:DCTH) is currently trading at $13.95, with a 20-day average volume of 335,331 shares. The stocks short-term technical outlook is mixed, as the 20-day SMA ($15.60) and 50-day SMA ($14.03) indicate recent downward pressure, while the 200-day SMA ($10.21) reflects longer-term upside momentum. The ATR of 0.81 signals moderate volatility. On the fundamental side, the companys market cap stands at $538.66M, with a forward P/E of 106.38, reflecting investor expectations of future earnings growth. The P/B ratio of 62.85 highlights a premium valuation relative to book value, while the P/S ratio of 23.79 underscores the markets confidence in the companys revenue potential. However, the lack of reported RoE suggests that profitability remains a key area of focus for investors.